Severe mental illness and European COVID-19 vaccination strategies

Livia De Picker; Marisa Casanova Dias; Michael  Benros; Benedetta Vai; Igor  Branchi; Francesco Benedetti; Alessandra  Borsini; Juan Carlos  Leza; Hilkka  Kärkkäinen; Miia  Männikkö; Carmine M  Pariante; Ekin Sönmez  Güngör; Anna  Szczegielniak; Ryad  Tamouza; A van der Markt; Paolo  Fusar-Poli; Julian  Beezhold; Marion  Leboyer

doi:10.1016/S2215-0366(21)00046-8

Severe mental illness and European COVID-19 vaccination strategies

Livia De Picker^*, Marisa Casanova Dias, Michael Benros, Benedetta Vai, Igor Branchi, Francesco Benedetti, Alessandra Borsini, Juan Carlos Leza, Hilkka Kärkkäinen, Miia Männikkö, Carmine M Pariante, Ekin Sönmez Güngör, Anna Szczegielniak, Ryad Tamouza, A van der Markt, Paolo Fusar-Poli, Julian Beezhold, Marion Leboyer

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

The EU advises prioritising vaccination for people whose health makes them particularly at risk for severe COVID-19, but leaves it to member states to decide which medical conditions get prioritised. Ethical, neuroscientific, and public health considerations have been used to prioritise individuals with severe mental illness (ie, psychotic disorders, bipolar disorders, and severe major depressive disorders).1, 2, 3 We systematically reviewed national COVID-19 vaccine deployment plans across 20 European countrie

Original language	English
Pages (from-to)	356-359
Number of pages	4
Journal	The Lancet Psychiatry
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/S2215-0366(21)00046-8
Publication status	Published - May 2021

Access to Document

10.1016/S2215-0366(21)00046-8

Cite this

De Picker, L., Dias, M. C., Benros, M., Vai, B., Branchi, I., Benedetti, F., Borsini, A., Leza, J. C., Kärkkäinen, H., Männikkö, M., Pariante, C. M., Güngör, E. S., Szczegielniak, A., Tamouza, R., van der Markt, A., Fusar-Poli, P., Beezhold, J., & Leboyer, M. (2021). Severe mental illness and European COVID-19 vaccination strategies. The Lancet Psychiatry, 8(5), 356-359. https://doi.org/10.1016/S2215-0366(21)00046-8

@article{61d7f9632ec04821a8be2aab398cc454,

title = "Severe mental illness and European COVID-19 vaccination strategies",

abstract = "The EU advises prioritising vaccination for people whose health makes them particularly at risk for severe COVID-19, but leaves it to member states to decide which medical conditions get prioritised. Ethical, neuroscientific, and public health considerations have been used to prioritise individuals with severe mental illness (ie, psychotic disorders, bipolar disorders, and severe major depressive disorders).1, 2, 3 We systematically reviewed national COVID-19 vaccine deployment plans across 20 European countrie",

author = "{De Picker}, Livia and Dias, {Marisa Casanova} and Michael Benros and Benedetta Vai and Igor Branchi and Francesco Benedetti and Alessandra Borsini and Leza, {Juan Carlos} and Hilkka K{\"a}rkk{\"a}inen and Miia M{\"a}nnikk{\"o} and Pariante, {Carmine M} and G{\"u}ng{\"o}r, {Ekin S{\"o}nmez} and Anna Szczegielniak and Ryad Tamouza and {van der Markt}, A and Paolo Fusar-Poli and Julian Beezhold and Marion Leboyer",

note = "Funding Information: This paper has been developed collaboratively and has received endorsements from the European College of Neuropsychopharmacology, European Psychiatric Association, European Federation of Associations of Families of People with Mental Illness, Global Alliance of Mental Illness Advocacy Networks-Europe, and European Union of Medical Specialists, Section of Psychiatry. The authors would like to express their utmost gratitude to our network of local representatives who helped to identify, collect and review the national strategy documents, and provided additional information derived from their personal clinical experience and the national psychiatric associations: Pavel Trancik (Czech Republic), Paula Mustonen (Finland), J{\"o}rdis Rausch (Germany), Thanos Khanellopoulos (Greece), Zetti Azvee (Ireland), Liene Berze (Latvia), Giovanni Grech (Malta), Morten Svendal Hatlen (Norway), Miguel Bajouco (Portugal), Celso Arango and Eduard Vieta (Spain), Stanko Medic, Amelie Kjellstenius, and Tove Mogren (Sweden). LJDP is a member of the European College of Neuropsychopharmacology Immunopsychiatry Thematic Working Group and the European Psychiatriac Association Committee on Education. LJDP reports grants from Boehringer-Ingelheim and Janssen R&D, outside the submitted work. MCD is vice president for Continuing Medical Education at the European Union of Medical Specialists, Section of Psychiatry. CMP received research and consultancy funding from Johnson & Johnson (2012–18) and Boehringer Ingelheim (2020) and is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer's Disease consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck, and Pfizer, outside the submitted work. CMP is also funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King's College London, and by a NIHR Senior Investigator Award. PF-P reports personal fees from Menarini, Angelini, and Lundbeck, outside the submitted work. ML reports personal fees from Janssen and Sanofi; grants from Otsuka, Lundbeck, and Roche, outside the submitted work. All other authors declare no competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = may,

doi = "10.1016/S2215-0366(21)00046-8",

language = "English",

volume = "8",

pages = "356--359",

journal = "Lancet psychiatry",

issn = "2215-0374",

publisher = "Elsevier Limited",

number = "5",

}

De Picker, L, Dias, MC, Benros, M, Vai, B, Branchi, I, Benedetti, F, Borsini, A, Leza, JC, Kärkkäinen, H, Männikkö, M, Pariante, CM, Güngör, ES, Szczegielniak, A, Tamouza, R, van der Markt, A, Fusar-Poli, P, Beezhold, J & Leboyer, M 2021, 'Severe mental illness and European COVID-19 vaccination strategies', The Lancet Psychiatry, vol. 8, no. 5, pp. 356-359. https://doi.org/10.1016/S2215-0366(21)00046-8

TY - JOUR

T1 - Severe mental illness and European COVID-19 vaccination strategies

AU - De Picker, Livia

AU - Dias, Marisa Casanova

AU - Benros, Michael

AU - Vai, Benedetta

AU - Branchi, Igor

AU - Benedetti, Francesco

AU - Borsini, Alessandra

AU - Leza, Juan Carlos

AU - Kärkkäinen, Hilkka

AU - Männikkö, Miia

AU - Pariante, Carmine M

AU - Güngör, Ekin Sönmez

AU - Szczegielniak, Anna

AU - Tamouza, Ryad

AU - van der Markt, A

AU - Fusar-Poli, Paolo

AU - Beezhold, Julian

AU - Leboyer, Marion

N1 - Funding Information: This paper has been developed collaboratively and has received endorsements from the European College of Neuropsychopharmacology, European Psychiatric Association, European Federation of Associations of Families of People with Mental Illness, Global Alliance of Mental Illness Advocacy Networks-Europe, and European Union of Medical Specialists, Section of Psychiatry. The authors would like to express their utmost gratitude to our network of local representatives who helped to identify, collect and review the national strategy documents, and provided additional information derived from their personal clinical experience and the national psychiatric associations: Pavel Trancik (Czech Republic), Paula Mustonen (Finland), Jördis Rausch (Germany), Thanos Khanellopoulos (Greece), Zetti Azvee (Ireland), Liene Berze (Latvia), Giovanni Grech (Malta), Morten Svendal Hatlen (Norway), Miguel Bajouco (Portugal), Celso Arango and Eduard Vieta (Spain), Stanko Medic, Amelie Kjellstenius, and Tove Mogren (Sweden). LJDP is a member of the European College of Neuropsychopharmacology Immunopsychiatry Thematic Working Group and the European Psychiatriac Association Committee on Education. LJDP reports grants from Boehringer-Ingelheim and Janssen R&D, outside the submitted work. MCD is vice president for Continuing Medical Education at the European Union of Medical Specialists, Section of Psychiatry. CMP received research and consultancy funding from Johnson & Johnson (2012–18) and Boehringer Ingelheim (2020) and is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer's Disease consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck, and Pfizer, outside the submitted work. CMP is also funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King's College London, and by a NIHR Senior Investigator Award. PF-P reports personal fees from Menarini, Angelini, and Lundbeck, outside the submitted work. ML reports personal fees from Janssen and Sanofi; grants from Otsuka, Lundbeck, and Roche, outside the submitted work. All other authors declare no competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/5

Y1 - 2021/5

N2 - The EU advises prioritising vaccination for people whose health makes them particularly at risk for severe COVID-19, but leaves it to member states to decide which medical conditions get prioritised. Ethical, neuroscientific, and public health considerations have been used to prioritise individuals with severe mental illness (ie, psychotic disorders, bipolar disorders, and severe major depressive disorders).1, 2, 3 We systematically reviewed national COVID-19 vaccine deployment plans across 20 European countrie

AB - The EU advises prioritising vaccination for people whose health makes them particularly at risk for severe COVID-19, but leaves it to member states to decide which medical conditions get prioritised. Ethical, neuroscientific, and public health considerations have been used to prioritise individuals with severe mental illness (ie, psychotic disorders, bipolar disorders, and severe major depressive disorders).1, 2, 3 We systematically reviewed national COVID-19 vaccine deployment plans across 20 European countrie

UR - http://www.scopus.com/inward/record.url?scp=85104324869&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(21)00046-8

DO - 10.1016/S2215-0366(21)00046-8

M3 - Comment/Letter to the editor

SN - 2215-0374

VL - 8

SP - 356

EP - 359

JO - Lancet psychiatry

JF - Lancet psychiatry

IS - 5

ER -

Severe mental illness and European COVID-19 vaccination strategies

Abstract

Access to Document

Other files and links

Cite this